AbbVie Expands Oxford R&D in £120m UK Investment

AbbVie has opened a 12,000 sq ft expansion of its Oxford R&D facility as part of more than £120 million invested and committed to UK life sciences, strengthening its immunology, neuroscience and oncology drug discovery capabilities. Announced on 4 November 2026, the expansion marks a substantial vote of confidence in the UK life sciences cluster at a time when big pharma is increasingly weighing international R&D allocation decisions against market access and reimbursement conditions.

The Oxford facility focuses on immunology, neuroscience and oncology, building on AbbVie’s October 2022 acquisition of Oxford-founded biotech DJS Antibodies. Jon Sedgwick, AbbVie’s Global Head of Discovery Research, positioned human biology and reverse translation as fundamental to the company’s approach for finding disease targets and combination therapies. Kelly Sanderson Schrems, General Manager of AbbVie UK, framed the broader £120m commitment around a competitive argument: countries that pair good patient access to innovative medicines with strong R&D infrastructure are best placed to attract continued investment. AbbVie employs more than 1,100 people across its UK sites in Oxford, Maidenhead and Marlow, with the Oxford expansion anchoring long-term UK R&D headcount growth.

The £120m commitment also covers academic collaboration and talent development, with AbbVie working with more than 100 UK universities and research organisations each year. A University of Oxford project studies how patients with certain inflammatory conditions respond to different treatments over the course of their disease, while AbbVie funds a postdoctoral programme at Oxford on the biological drivers of inflammatory diseases. The investment lands against a backdrop of big pharma reassessing UK R&D positioning following recent sector commentary on access, reimbursement and the competitiveness of UK life sciences infrastructure. AbbVie’s expansion sends a clear signal that Oxford remains a strategically important discovery location, particularly for immunology and inflammatory disease research, where the local academic ecosystem offers substantial scientific depth. The move complements AbbVie’s wider 2026 dealmaking activity, including its reported $1.38bn IBD licensing deal with Nxera.

The commercial signal is a continuing UK life sciences investment story where Oxford’s immunology and inflammation research cluster is attracting big pharma discovery capital against a more cautious broader UK pharma investment backdrop. Academic partnership models remain central to location decisions. Expect sustained big pharma investment in UK R&D clusters and continued focus on immunology and neuroscience through 2027.

For the latest updates and in-depth insights into the world of Life Science, including breakthrough treatments, industry trends, and regulatory news, contact Bailey Osborne today!